Compare ResMed Inc. (RMD) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Wayfair Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Wayfair Inc trades at $100.12 (market cap $13.69B). The key difference: ResMed Inc. is far larger — about 2.3× Wayfair Inc's market cap, and ResMed Inc. pays a 1.19% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals.
| RMD | W | |
|---|---|---|
Market Cap | $31.89B | $13.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $283.28 | $119.05 |
52-Week Low | $182.82 | $57.40 |
Enterprise Value | $31.24B | $16.03B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Wayfair (W) trades at $99.96, up 0.53% today, with a bullish technical signal supported by moving averages. The stock shows strong revenue growth of 7.5% year-over-year in Q2 2026 and has beaten earnings estimates in two of the last three quarters. Recent positive sentiment follows the company's 10th store announcement and a golden cross technical pattern. However, the company continues to report net losses with a -2.49% net income margin and carries significant debt with a 95.11% debt-to-asset ratio.
Wayfair presents a mixed investment case with strong revenue momentum and market share gains offset by persistent profitability challenges. The consensus price target of $125.14 suggests 25% upside potential, supported by 53.57% analyst buy ratings. Key risks include ongoing net losses, high leverage, and consumer spending sensitivity. The stock's technical strength and expansion initiatives provide catalysts, but profitability improvement remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
